Skip Navigation LinksDocuments

  
  
  
  
  
ctmeeting121119_burger.pdf
  
2/28/2013 8:21 AMRussell Cotten
ctmeeting121119_gee.pdf
  
2/28/2013 8:22 AMRussell Cotten
ctmeeting121119_gunter.pdf
  
2/28/2013 8:44 AMRussell Cotten
ctmeeting121119_janssen1.pdf
  
2/28/2013 8:25 AMRussell Cotten
ctmeeting121119_janssen2.pdf
  
2/28/2013 8:26 AMRussell Cotten
ctmeeting121119_mcniece.pdf
  
2/28/2013 8:27 AMRussell Cotten
ctmeeting121119_niss.pdf
  
2/28/2013 8:34 AMRussell Cotten
FDA-CTLM-180130-Presentation1.pdf
  
4/24/2018 12:30 PMGeoff Duncan
FDA-CTLM-180130-Presentation2.pdf
  
4/24/2018 12:31 PMGeoff Duncan
FDA-CTLM-180130-Presentation3.pdf
  
4/24/2018 12:31 PMGeoff Duncan
FDA-CTLM-180130-Presentation4.pdf
  
4/24/2018 12:31 PMGeoff Duncan
FDA-CTLM-180130-Presentation5.pdf
  
4/24/2018 12:31 PMGeoff Duncan
Presentation 1a_CQAs for CGT Products_M. Myers.pdf
  
2/23/2017 3:18 AMMr. Frank Berry
Presentation 1b_Critical Quality Attributes During PD Lifecycle_T. Finn.pdf
  
2/23/2017 3:17 AMMr. Frank Berry
Presentation 2_Stds in Development of Regen Med Products_J. Arcidiacono.pdf
  
2/23/2017 3:17 AMMr. Frank Berry
Presentation 3a_Reference Standards for Cell and Gene Therapy_B. Dropulic.pdf
  
2/23/2017 3:17 AMMr. Frank Berry
Presentation 3b_Product Characterization in Cellular Therapy_R. Hulspas.pdf
  
2/23/2017 3:17 AMMr. Frank Berry
Presentation 4_SCB-For Cell and Gene and Regen Therapies_M. Mendicino.pdf
  
2/23/2017 3:17 AMMr. Frank Berry
Presentation 5a_Relevant Communicable Diseases in HCTPs_P. Warkentin.pdf
  
2/23/2017 3:17 AMMr. Frank Berry
Presentation 5b_Infectious Disease Screening and Testing_M. McClure.pdf
  
2/23/2017 3:17 AMMr. Frank Berry
Presentation 6_Labeling of Cellular Products_O. Sturtevant.pdf
  
2/23/2017 3:17 AMMr. Frank Berry